STOCK TITAN

Alnylam Pharmaceuticals (ALNY) director receives 4,393 stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ALNYLAM PHARMACEUTICALS, INC. director Benjamin Cravatt reported a compensation-related stock option grant. He received options to buy 4,393 shares of common stock at an exercise price of $295.63 per share. The options vest in three equal annual installments starting on the first anniversary of the grant date and expire in 2036. Following this grant, he holds 4,393 derivative securities directly.

Positive

  • None.

Negative

  • None.
Insider Cravatt Benjamin
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 4,393 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 4,393 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 4,393 options Stock Option (Right to Buy) grant to director Benjamin Cravatt
Exercise price $295.63 per share Conversion or exercise price for the stock options
Total derivative holdings 4,393 options Total derivative securities following the reported transaction
Vesting schedule 1/3 annually over 3 years One third vests on each of the first three anniversaries of grant
Option expiration date June 1, 2036 Expiration date of the stock option grant
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 295.6300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The stock option will vest as to one third of the shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-01T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cravatt Benjamin

(Last)(First)(Middle)
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$295.6306/01/2026A4,39306/01/2027(1)06/01/2036Common Stock4,393$04,393D
Explanation of Responses:
1. The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant.
Brett Budzinski, Attorney-in-fact for Benjamin Cravatt06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ALNY (ALNY) director Benjamin Cravatt report in this Form 4 filing?

Benjamin Cravatt reported receiving a stock option grant for 4,393 shares of ALNY common stock. The options are compensation-related, not an open-market trade, and give him the right to buy shares at a fixed exercise price in the future.

How many Alnylam Pharmaceuticals (ALNY) stock options were granted to Benjamin Cravatt?

Benjamin Cravatt was granted stock options covering 4,393 shares of Alnylam common stock. These derivative securities give him the right to purchase that number of shares, subject to vesting and other terms described in the filing’s footnote.

What is the exercise price of Benjamin Cravatt’s ALNY stock options?

The granted options have an exercise price of $295.63 per share. This means Cravatt can purchase Alnylam common stock at $295.63 for each option, once vested and before the options expire, regardless of the market price at that time.

When do Benjamin Cravatt’s Alnylam stock options vest according to the Form 4?

The stock options vest in three equal installments on the first, second, and third anniversaries of the grant date. Each year, approximately one third of the 4,393 options becomes exercisable, aligning the award with multi-year service at Alnylam.

What is the expiration date of the ALNY stock options granted to Benjamin Cravatt?

The stock options granted to Benjamin Cravatt expire on June 1, 2036. After that expiration date, any unexercised options become worthless, so they must be exercised, if at all, between vesting and that 2036 expiration.

How many derivative securities does Benjamin Cravatt hold after this ALNY option grant?

Following the reported transaction, Benjamin Cravatt beneficially owns 4,393 derivative securities related to Alnylam common stock. This figure matches the size of the new option grant, reflecting his position as reported in this specific Form 4 filing.